Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine (Q45416054)

14 December 2017

title

Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine (English)

1 reference

14 December 2017

2

David C Montefiori

1 reference

14 December 2017

9

Bernard Moss

1 reference

14 December 2017

6

Linda S Wyatt

1 reference

14 December 2017

10

Rama Rao Amara

1 reference

14 December 2017

7

Patricia L Earl

1 reference

14 December 2017

3

Francois Villinger

1 reference

14 December 2017

1

Harriet L Robinson

1 reference

14 December 2017

James E Robinson

4

1 reference

14 December 2017

Sunita Sharma

series ordinal

5

1 reference

14 December 2017

Harold M McClure

series ordinal

8

1 reference

14 December 2017

language of work or name

English

0 references

publication date

5 June 2006

1 reference

14 December 2017

1 reference

14 December 2017

volume

352

1 reference

14 December 2017

issue

2

1 reference

14 December 2017

page(s)

285-294

1 reference

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Origin and differentiation of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

A vaccine for HIV type 1: the antibody perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Antibody vs. HIV in a clash of evolutionary titans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

HIV preferentially infects HIV-specific CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony sti

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Progress toward an HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Follicular homing T helper (Th) cells and the Th1/Th2 paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

The antiviral activity of antibodies in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Cytokines and costimulatory molecules as genetic adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

New hope for an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Mouse and human dendritic cell subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Identifying epitopes of HIV-1 that induce protective antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

7 January 2021

Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

7 January 2021

Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

7 January 2021

Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

7 January 2021

Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

7 January 2021

A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.011

7 January 2021

10.1016/J.VIROL.2006.02.011

Identifiers

DOI

1 reference

14 December 2017

1 reference